Thymosin Alpha-1

Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide naturally produced by the thymus gland, which plays a central role in immune system development and regulation. The thymus is most active during childhood and progressively atrophies with age — a process called thymic involution — which contributes to the age-related decline in immune function (immunosenescence). Thymosin Alpha-1 supplementation aims to restore some of this lost immune capacity. Ta1 works primarily by activating dendritic cells (the "sentinels" of the immune system) and enhancing T-cell function, particularly the differentiation and activity of cytotoxic T-cells (CD8+) and helper T-cells (CD4+).

It also promotes the maturation of T-cells in the thymus and enhances the production of cytokines like IL-2 and interferon-gamma. Thymosin Alpha-1 is approved as a prescription drug (Zadaxin) in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy. It has been used extensively in clinical settings for over two decades, with a well-established safety profile. During the COVID-19 pandemic, it gained attention for its potential to improve outcomes in severe infections by restoring T-cell function in immunocompromised patients.